Regorafenib-Related Myocardial Injury during Atrial Fibrillation.
Multikinase inhibitors with an anti-vascular endothelial growth factor effect have been reported to increase the risk of myocardial infarction or ischemia. We have presented the case of a 72-year-old male who had a metastatic gastrointestinal stromal tumor for which he received targeted therapy and who was admitted to our hospital for recurrent episodes of myocardial injury during atrial fibrillation. Coronary angiography showed insignificant coronary artery stenosis. We also reviewed the incidence of cardiovascular events in patients receiving regorafenib, and the current understanding of the mechanism of targeted therapy-induced myocardial ischemia/infarction.


BACKGROUND
Multikinase inhibitor • Myocardial infarction • Myocardial ischemia • Vascular endothelial growth factor.
The Division of Cardiology, Department of Internal Medicine;
Fu-Chih
FC
Hsiao
Division of General Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan.
Chun-Nan
CN
Yeh
The Division of Cardiology, Department of Internal Medicine;
Pao-Hsien
PH
Chu